Cat. No.
MABL-3669
Application
IHC-F, IHC-P, Block, ELISA, FC, IF
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
M200 (Volociximab)
From
Recombinant Antibody
Specificity
This antibody is specific for human α5β1 integrin. Cross-reactivity studies revealed no binding to other human integrins such as α3β1, αvβ3, or αvβ5. It does, however, bind to α5β1 in the vasculature of cynomolgus monkeys, but not in mice. α5β1 is part of the integrin superfamily—glycoprotein transmembrane receptors that interact with ligands such as fibronectin, vitronectin, laminins, and collagens. This receptor plays a key role in processes including inflammation, cell proliferation, angiogenesis, and tumor metastasis.
Alternative Names
Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha- F; VLA-5; CD49e.
UniProt
P08648
Immunogen
Heterodimeric α5β1Fc fusion protein
Application Notes
This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM,EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse–human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968; Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009; DOI: 10.1007/978-1- 59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 µg/mL, with 2–3× accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011; PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.
Antibody First Published
Ramakrishnan et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. PMID:17024968
Note on publication
Describes the role of α5β1 integrin in the progression of angiogenesis, and the generation of Volociximab, a chimeric monoclonal antibody whose in vitro and in vivo use is evaluated for therapeutic use.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
